scholarly journals Renal safety and efficacy of angiotensin receptor‐neprilysin inhibitor: A meta‐analysis of randomized controlled trials

2020 ◽  
Vol 45 (6) ◽  
pp. 1235-1243
Author(s):  
Yu Feng ◽  
Yongmei Yin ◽  
Rong Deng ◽  
Haonan Li
Keyword(s):  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Angiotensin Receptor ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Neprilysin Inhibitor ◽  
Angiotensin Receptor Neprilysin Inhibitor ◽  
Renal Safety

scholarly journals Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials

Cardiology ◽  
2020 ◽  
Vol 145 (9) ◽  
pp. 589-598 ◽  
Author(s):  
Qiang Geng ◽  
Rongqiang Yan ◽  
Zhengzhong Wang ◽  
Fangjie Hou
Keyword(s):  
Blood Pressure ◽  
Randomized Controlled Trials ◽  
Angiotensin Receptor Blockers ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering Effect ◽  
Randomized Controlled ◽  
Neprilysin Inhibitor

Background: LCZ696 (sacubitril/valsartan), a first-in-class angiotensin receptor-neprilysin inhibitor, can significantly reduce blood pressure in patients with heart failure. We performed this meta-analysis to determine the antihypertensive effect of LCZ696 in patients with hypertension. Methods: Randomized controlled trials were searched in MEDLINE, the Cochrane Library, and Clinicaltrials.gov. Twelve studies with a total of 6,064 participants were included. Results: Compared with angiotensin receptor blockers (ARBs), LCZ696 100 mg caused a significant reduction in systolic blood pressure (SBP) (mean difference [MD] –1.58 mm Hg, 95% confidence interval [CI] –2.09 to –1.07, p < 0.05) and diastolic blood pressure (DBP) (MD –0.66 mm Hg, 95% CI –0.98 to –0.33, p < 0.05). LCZ696 200 mg caused a significant reduction in SBP (MD –4.94 mm Hg, 95% CI –6.54 to –3.35, p < 0.05), DBP (MD –2.24 mm Hg, 95% CI –2.74 to –1.75, p < 0.05), 24-h ambulatory SBP (24 h ASBP; MD –3.69 mm Hg, 95% CI –4.80 to –2.58, p < 0.05), and 24-h ADBP (MD –1.71 mm Hg, 95% CI –2.13 to –1.28, p < 0.05). LCZ696 400 mg caused a significant reduction in SBP (MD –6.25 mm Hg, 95% CI –7.90 to –4.61, p < 0.05), DBP (MD -2.30 mm Hg, 95% CI –2.80 to –1.80, p < 0.05), 24-h ASBP (MD –4.31 mm Hg, 95% CI –6.56 to –2.07, p < 0.05), and 24 h ADBP (MD –1.69 mm Hg, 95% CI –2.59 to –0.79, p < 0.05). Compared with LCZ696 200 mg, LCZ696 400 mg caused a significant reduction in SBP (MD 1.71 mm Hg, 95% CI 1.15 to 2.27, p < 0.05), DBP (MD 0.90 mm Hg, 95% CI 0.65 to 1.16, p < 0.05), 24-h ASBP (MD 1.50 mm Hg, 95% CI 0.84 to 2.17, p < 0.05), and 24-h ADBP (MD 0.76 mm Hg, 95% CI 0.47 to 1.06, p < 0.05). Conclusions: The blood pressure-lowering effect of LCZ696 is dose-related. This meta-analysis confirms the antihypertensive effects of LCZ696.

Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials

2019 ◽  
Vol 145 (7) ◽  
pp. 1795-1809 ◽  
Author(s):  
Tarek Haykal ◽  
Mahmoud Barbarawi ◽  
Yazan Zayed ◽  
Anitha Yelangi ◽  
Harsukh Dhillon ◽  
...  
Keyword(s):  
Primary Prevention ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Prevention Of Cancer
Sign in / Sign up

Export Citation Format

Share Document